- Company
- Arexvy opening the era of RSV vaccine
- by Whang, byung-woo May 15, 2025 06:22am
- As GSK launches the respiratory syncytial virus (RSV) vaccine Arexvy in South Korea, it will challenge the market on a full-scale. Arexvy is already expanding its market dominance in the global market with its strength as the first RSV vaccine. The company will likely focus on expanding vaccine awareness as it opens the RSV vaccine market for
- Company
- Will a new trend emerge for liver cancer treatment?
- by Moon, sung-ho May 15, 2025 06:22am
- With new anticancer drugs entering the liver cancer treatment market, where combination therapy has been gaining prominence, attention is focused on whether a paradigm shift will occur. This is because a new competitive landscape is forming with the arrival of newly approved drugs and newly reimbursed drugs. According to industry sour
- Company
- 'Adempas' for pulmonary hypertension closer to obtain reimb
- by Eo, Yun-Ho May 14, 2025 06:11am
- A new reimbursable treatment option for pulmonary hypertension is anticipated to be introduced. According to industry sources, Bayer Korea has finally reached an agreement with the National Health Insurance Service (NHIS) for its 'Adempas (riociguat).' Accordingly, after 10 years since it was approved in South Korea, Adempas will likel
- Company
- U.S. executive order on drug price cuts raises hope
- by Kim, Jin-Gu May 14, 2025 06:10am
- U.S. President Donald Trump has signed an executive order to significantly reduce drug prices in the United States. This measure, which focuses on significantly reducing U.S. drug prices in line with overseas prices, is expected to have a positive effect on domestic biosimilars. However, some predict that the expected effects of this execu
- Company
- How has Leqembi changed the clinical site in 6 months?
- by Moon, sung-ho May 14, 2025 06:09am
- The overall treatment system on-site has been changing with the introduction of Leqembi, a new dementia drug that was released 6 months ago in Korea. In response, experts are evaluating the therapeutic effects and side effects of Leqembi (lecanemab, Eisai Korea) while demanding improvements to the health insurance reimbursement system in vari
- Company
- Vyloy quickly lands in general hospitals in Korea
- by Eo, Yun-Ho May 13, 2025 06:07am
- Vyloy, a targeted anticancer drug for gastric cancer, may be prescribed at general hospitals in Korea. According to industry sources, Vyloy (zolbetuximab), a Claudin 18.2-positive gastric cancer targeted therapy developed by Astellas Korea, is now available for prescription at the Big 5 tertiary hospitals in Korea, including Samsung Medic
- Company
- Mounjaro provides more weight loss than Wegovy
- by Eo, Yun-Ho May 13, 2025 06:06am
- Research results found Mounjaro brings more weight loss than its competitor Wegovy. On the 12th, Lilly announced the detailed results of the SURMOUNT-5 Phase IIIb open-label clinical trial directly comparing Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, and Wegovy (semaglutide), a GLP-1 receptor agonist. The study, which
- Company
- U.S. pharmaceutical imports rise twofold amid tariff concern
- by Kim, Jin-Gu May 13, 2025 06:05am
- U.S. drug imports have nearly doubled in a year. This is believed to be the result of frontline pharmaceutical and biotech companies focusing on securing inventory in expectation of U.S. President Donald Trump's drug tariff imposition. According to Korea Biotechnology Industry Organization (KoreaBIO) on the 12th, the U.S. The United States C
- Company
- 'Retevmo' also seeks thyroid cancer reimbursement
- by Eo, Yun-Ho May 12, 2025 05:59am
- The RET-targeted cancer therapy 'Retevmo' seeks insurance reimbursement listing of its medullary thyroid cancer indication. According to sources, Lilly Korea recently submitted reimbursement applications simultaneously for the non&8211;small cell lung cancer indication and medullary thyroid cancer indication of the RET (REarranged during
- Company
- Pemazyre lands in major hospitals in Korea
- by Eo, Yun-Ho May 12, 2025 05:59am
- Pemazyre, a treatment for intrahepatic bile duct cancer(cholangiocarcinoma), may now be prescribed at tertiary hospitals in Korea. According to industry sources, Handok's Pemazyre (pemigatinib) has passed the drug committee (DC) of the Big 5 general hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital,
